Since anti-Stab1 therapies are already in Phase I/II clinical trials [28] and Stab1/Stab2 inhibition has therapeutic promise in atherosclerosis [8], non-homeostatic disease models of genetic Stabilin deficiency might allow predicting side-effects of anti-Stabilin antibodies. The gene discussed is STAB1; the disease is atherosclerosis.